Liraglutide, an investigational nursing contained by benefit of hue 2 diabetes down augmentation by way of Novo Nordisk, better the offering of pancreatic beta cell to veil insulin in general community essential type 2 diabetes, according to findings from a late-breaking screening today at the 66th annual scheduled time of the American Diabetes Association (ADA).
(1) The findings from the den, bit of a larger, double-blind, placebo-controlled, randomized examination conduct complete 14 weeks,(2) clearly show that liraglutide increased the maximum dimensions of beta cells to secrete insulin. In calculation, insulin secretion be increased in the so-called "first phase" insulin reply, which be by means of regular diminish in patients with type 2 diabetes.
The larger trial showed that liraglutide reduced loftiness of A1C, the initial endpoint and a weigh of a person's be encode to blood glucose level over yesteryear two to three months. Additionally, participant by the supreme dose of liraglutide nowhere to be found vitally more weightiness than act upon those on placebo by the failure of the 14-week study.
"The majority of type 2 diabetes end to come together, and we stipulation to research and develop unsullied dream therapy for the surroundings," said study investigator Sten Madsbad, M.D., DMSc., Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark. "We be agitated by these grades as they denote that liraglutide monotherapy significantly improve blood glucose dictate in need stake of essence or lesser hypoglycemia, is all right tolerate, subjugate article weight and may aid amend the body's ability to cultivate insulin." Pancreatic beta cells are liable for produce insulin, a hormone that help hauling glucose from the bloodstream into body cells, providing them an celebrated wellspring of gusto and prevent blood glucose from becoming terrifyingly lofty. People with type 2 diabetes, the peak undisputed be of the condition, do not produce ample insulin or their body cells are minor numeral moody to it. While diet, use and weight sore may most primitive prolong control of blood glucose levels (glycemic control), beta cell manoeuvre decline over episode, necessitate therapy with one or more oral antidiabetic (OAD) agents that thrill insulin secretion or heighten insulin inflammation. As beta cell function further declines and OAD therapy ultimately fail, insulin therapy is required.
One dilemma with insulin and a few OAD therapies is that they can use up blood glucose levels as well shrunken (hypoglycemia), which can also be ramshackle. Liraglutide act to lower blood glucose with the sole purpose when levels become too high,(3,4) and study salute it is associated with a low risk of hypoglycemia.(5,6) Furthermore, in animal model, liraglutide hold be shown to nose-dive beta-cell apoptosis (programmed cell death) and increase beta-cell mass.(7,8,9,10,11) Studies and findings The larger study was a double-blind, placebo-controlled, randomized trial conducted over 14 weeks and integrated 165 patients with type 2 diabetes who be in earlier times luxury with diet or a individual oral antidiabetic agent. After an opening four-week washout spell, patients were randomized to one of three once-daily dose of liraglutide (0.65 mg, 1.25 mg and 1.9 mg) or placebo.
Improved blood glucose control was get done with liraglutide monotherapy. Levels of A1C, the primary endpoint, were significantly reduced compare to placebo in all liraglutide treatment flock (p0.0001). At the highest dose, the average narrowing of A1C vs. placebo was 1.74 percent. Between 43 and 50 percent of patients who received liraglutide and 8 percent on placebo manage an A1C level of less than or synonymous to 7 percent. The improved glycemic control was achieved devoid of major or minor hypoglycemic interval. In addition, patients on liraglutide have a reduction in bodyweight, with those on the highest dose losing harshly three kg (6.6 pounds) vs baseline and 1.2 kg (2.5 pounds) vs placebo after 14 weeks.
Liraglutide was well tolerated by participants in all groups, with the key adverse actions female united to the gastrointestinal (GI) net. Nausea, which was sophisticated by 10 percent of participants in the high-dose group, and diarrhea, were the most common adverse events; on the other hand, the frequency of all GI events decline over time.
The late-breaking findings were from a subgroup of 39 participants who were also part of the larger trial. At baseline and after 14 weeks, these participants undergo median test to evaluate first-phase insulin secretion and maximal beta cell insulin secretory capacity. Of 39 participants who inaugurate the study, 28 completed the 14 weeks of treatment. The two superior doses of liraglutide (1.25 mg and 1.9 mg) significantly increased maximal beta cell insulin secretory capacity compared to placebo by 114 percent and 97 percent, respectively (p0.05 for both doses), and first-phase insulin secretion by 124 percent and 107 percent, respectively (p0.05).
About liraglutide Currently in period 3 clinical trial, liraglutide is a long-acting analog(12) of the essentially occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is speedily faulty downhill in the body and here manner impossible as a therapy for type 2 diabetes. GLP-1 is released from the gastrointestinal tract upon ingestion of diet. When glucose levels become too high, GLP-1 trigger the deliverance of insulin from the pancreas(13) and decrease the secretion of glucagon,(14) a hormone that puff glucose combination in the liver. GLP-1 release insulin in a glucose-dependent dummy run, import that it only triggers insulin secretion if blood glucose is too high. This countenance results in a low risk of hypoglycemia, which has been confirmed in a digit of studies where GLP-1 was infused intravenously or subcutaneously.(15,16,17,18,19,20) Studies to date show that liraglutide significantly improves glycemic control in monotherapy and in muddle therapy with metformin.(21,22,23,24) Clinical trials have shown liraglutide: -- Acts in a glucose-dependent manner, meaning that it agitate insulin secretion and inhibit glucagon secretion only when blood glucose levels are higher than middle-of-the-road.(25,26) -- Has a low risk of hypoglycemia.(27,28) -- Improves sight of beta cell function.(29,30) -- Is not associated with weight gain.(31) -- Is associated with balmy to annoyance and transient GI haunch effects. (32,33) -- Is right for once-daily domination.
Novo Nordisk is a healthcare organization with an 80-year precedent of cleanness and glory in diabetes awareness to trifle. In addition to diabetes care, Novo Nordisk has a overriding class in pen such as hemostasis running, malignancy hormone therapy, and hormone therapy for women. Novo Nordisk's conglomerate is driven by the Triple Bottom Line: a commitment to monetary success, birth authority, and national fault to body and consumers. With headquarters in Denmark, Novo Nordisk employ higher than 22,500 employees in 79 countryside, and market its products in 179 countries. Novo Nordisk's B quota are down on the pigs exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the simile 'NVO'. For intercontinental numbers, phone call in ; for United States information, visit References: (1) Vilsboell T, Brock B, Perrild H, et al. 14 weeks of liraglutide therapy in subject with T2DM significantly improves 1st phase insulin secretion and maximal beta-cell secretory capacity. Late- breaking oral presentation (abstract 750195) at: 66th annual meeting of the American Diabetes Association, Washington, DC, June 9-13, 2006.
(2) Vilsboell T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of any major or minor hypoglycemic episodes in subjects with type 2 diabetes. Oral presentation (abstract # 115-OR) at: 66th annual meeting of the American Diabetes Association, Washington, DC, June 9-13, 2006.
(3) Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 uninspired liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduce endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.
(4) Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, Galecki A, Halter JB. The GLP-1 derivative NN2211 even out beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791.
(5) Matthews S et al. A long-acting GLP-1 derivative, NN2211: its lug supremacy of in the treatment of type 2 diabetes. Poster 678. Presented at: European Association for the Study of Diabetes annual meeting, Budapest, Hungary, September, 2002.
(6) Saad et al. The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with Type 2 diabetes Diabetologia 2002;45(Suppl 2)A44. Presented at: European Association for the Study of Diabetes annual meeting, Budapest, Hungary, September, 2002.
(7) Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, et al. GLP-1 derivative liraglutide in rats with beta-cell lesser amount force of metabolic enumerate on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-132.
(8) Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. The long-acting GLP-1 derivative, NN2211, ameliorates glycemia and increase Beta-cell mass in diabetic mice. Am J Physiol Endocrin Metab 2002;283:E745-E752.
(9) Bregenholt S et al. The GLP-1 analogue, NN2211, inhibits unmarried fatty acid-induced apoptosis in primary rat b-cells. Diabetologia 2001;44(S1):A19.
(10) Bregenholt S et al. The GLP-1 derivative NN2211 inhibits cytokine- induce apoptosis in primary rat b-cells. Diabetes 2001:50(S2):A31.
(11) Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005 May 6;330(2):577-84.
The switch to Halford's research be conception how the herpes simplex virus overcome the body's coarse defenses.
(13) Vilsboell et al. Defective amplification of the in arrears phase insulin response to glucose by GIP in obese Type II diabetic patients Diabetologia 2002;45:1111-1119 (14) Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.
(15) Rachman J et al. Near-normalisation of diurnal glucose concentration by ceaseless administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997 Feb;40(2):205-11.
(16) Toft-Nielsen MB et al Determinants of the usefulness of glucagon- in fasten propinquity to peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60.
(17) Zander M et al Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care. 2004 Aug;27(8):1910-4.
(18) Zander M et al Effect of 6-week trajectory of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet.
2002 Mar 9;359(9309): 824-30.
(19) Zander M et al Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care. 2001 Apr;24(4):720-5.
(20) Meneilly GS et al Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003 Oct;26(10):2835-41.
(21) Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long- acting GLP-1 analogue, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005 Aug;22(8):1016-23.
(22) Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body slog, and 24-h energy costs in patients with type 2 diabetes. Diabetes Care. 2004 Aug;27(8):1915-21.
(23) Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004 Jun;27(6):1335-42.
(24) Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.
(25) Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.
(26) Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, Galecki A, Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791.
(27) Matthews S et al. A long-acting GLP-1 derivative, NN2211: its use in the treatment of type 2 diabetes. Poster 678. Presented at: European Association for the Study of Diabetes annual meeting, Budapest, Hungary, September, 2002.
(28) Saad et al. The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with Type 2 diabetes Diabetologia 2002;45(Suppl 2)A44. Presented at: European Association for the Study of Diabetes annual meeting, Budapest, Hungary, September, 2002.
(29) Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 May;53(5):1187-94.
(30) Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, Galecki A, Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791.
(31) Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004 Jun;27(6):1335-42.
(32) Ibid (33) Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long- acting GLP-1 analog, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabetes Med. 2005 Aug;22(8):1016-23.
Novo Nordisk/cgi-bin/prnh/20020404/NVOLOGO
Visit ampills
Buy mircette acne. New generic drugs on AmPills.com store